Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
Robert F. Kennedy Jr. at Senate Finance Committee Hearing
August 27, 2025 2:46 AM 2 min read

Robert Kennedy Jr Tells Trump He's On Course To Identify 'Interventions' That Are 'Certainly Causing Autism' — Promises Announcements Next Month

by Shomik Sen Bhattacharjee Benzinga Staff Writer
Follow

Health and Human Services Secretary Robert F. Kennedy Jr. said Tuesday he is on track to identify "interventions" that are "certainly causing autism" and to outline possible ways to address them by September, after President Donald Trump pressed him for an update during a Cabinet meeting.

Robert Kennedy Jr. Promises Trump Announcements In September

"The autism is such a tremendous horror show… How are you doing?" Trump asked, according to a report by The Hill. "We are doing very well… We will have announcements as promised in September, finding interventions… now that are clearly almost certainly causing autism," Kennedy Jr. replied.

In April, Kennedy Jr. vowed to determine the cause of rising autism diagnoses, calling it an "epidemic" that "dwarfs the COVID epidemic." He repeated the theme in radio remarks later that month, drawing criticism from advocates who found the language stigmatizing.

See Also: Elizabeth Warren Says ‘Claim’ EV Tax Breaks Before Trump ‘Rips Them Away’

Experts Cite Detection Gains Behind Rising Autism Diagnoses

Federal data show autism is commonly identified today. About 1 in 31 U.S. children aged 8 were identified with autism in 2022, according to the CDC. Among adults, estimates suggest roughly 1 in 45 Americans are on the spectrum. Many experts attribute rising figures over decades largely to broadened diagnostic criteria, improved screening and awareness, not a single new cause.

Kennedy’s Loud Claims Against Vaccines Have Repeatedly Met Criticism

Major autism organizations and medical experts caution that there is no credible evidence that vaccines cause autism, a theory Kennedy has advanced for years. The Autism Society, which is a national charitable organization dedicated to improving the lives of individuals on the autism spectrum, said the administration's promise to pinpoint and "eliminate" exposures that "cause" autism is misleading and risks harm.

It is worth noting that researchers and independent fact-checkers have repeatedly found vaccine–autism claims unsupported by science.

Photo Courtesy: Maxim Elramsisy on Shutterstock.com

Read Next: OpenAI Sued After Parents Say Empathy-Mimicking ChatGPT Gave Their Teen Detailed Suicide Instructions While AI Company’s Valuation Soared

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
Health CareGeneralAutismDonald Trump
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter

Kennedy's broader record on vaccines has drawn sustained scrutiny since his selection and confirmation push, including concerns from policy scholars and physicians about misinformation and pressure on vaccine programs. Markets and health leaders reacted when Trump first floated Kennedy for a senior health role in late 2024 and has since led to high-profile resignations and disputes over vaccine policy.

Comments
Loading...